Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Medulloblastoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Metastatic Breast Cancer 1Gliosarcoma 1Familial ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

pyrotinib 1Lapatinib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER2 Positive Metastatic Breast Cancer × Lapatinib × Clear all
NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡